Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

Various factors contribute to disparities in 30-day readmission rates following allogeneic hematopoietic stem cell transplantation (allo-HCT) among patients with acute myeloid leukemia (AML), ...